Affiliation:
1. National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206.
Abstract
The in vivo activity of amikacin, used alone or in combination with rifabutin or clofazimine or both, was assessed in the treatment of early and established Mycobacterium avium complex infections in beige mice. Amikacin given alone at a dose of 50 mg/kg, in one, two, or three divided doses, showed remarkable activity. Addition of clofazimine increased the activity significantly, but addition of the third drug, rifabutin, did not further improve the results. Amikacin-containing regimens are worthy of consideration for investigations in patients with M. avium complex infections.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex;Bertram M. A.;J. Infect. Dis.,1986
2. Release of superoxide anion (O°) from resident and activated mouse peritoneal macrophages infected with Mycobacterium intracellulare;Gangadharam P. R. J.;Am. Rev. Respir. Dis.,1984
3. An acute infection model for Mycobacterium intracellulare disease using beige mice. Preliminary results;Gangadharam P. R. J.;Am. Rev. Respir. Dis.,1983
4. Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions;Gangadharam P. R. J.;Antimicrob. Agents Chemother.,1988
5. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections;Gangadharam P. R. J.;Am. Rev. Respir. Dis.,1987
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献